Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × Observation × Clear all

Status

Sponsor Class

OTHER 3 NIH 1 NETWORK 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1 Dermatologic 1

Conditions

Neoplasms 6 Breast Neoplasms 6 Prostatic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Carcinoma, Hepatocellular 3 Small Cell Lung Carcinoma 2 Lung Neoplasms 2 Vulvar Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Trauma, Nervous System 1 Thoracic Injuries 1 Stomach Neoplasms 1 Skin Neoplasms 1 Rectal Neoplasms 1 Radiculopathy 1 Pneumonia 1 Pathologic Complete Response 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Melanoma 1 Lymphoma 1 Lung Diseases, Interstitial 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, B-Cell 1 Leukemia 1 Laryngeal Neoplasms 1 Klippel-Feil Syndrome 1

Interventions

pembrolizumab 164 Nivolumab 112 Ipilimumab 93 Dacarbazine 44 trametinib 36 dabrafenib 34 Vemurafenib 33 binimetinib 23 atezolizumab 23 Temozolomide 21 cemiplimab 18 Paclitaxel 18 encorafenib 17 spartalizumab 16 cobimetinib 15 Carboplatin 14 talimogene laherparepvec 13 Cisplatin 13 Cyclophosphamide 11 lenvatinib 10 Pemetrexed 10 Gemcitabine 10 Docetaxel 10 durvalumab 9 Drug Therapy 9 Bevacizumab 9 130-nm albumin-bound paclitaxel 9 tremelimumab 8 relatlimab 8 Injections 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06887348 2026-01-12

RPx

Replimune Inc.

DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡